Corporate Strategy Case Study

Divesting Ranbaxy’s Family Business to Daiichi Sankyo - Is it a right move?

OR

Abstract:
Ranbaxy, India's largest pharmaceutical company is an integrated, research-based enterprise producing a wide range of quality, affordable generic medicines, trusted by health care professionals and patients across geographies. It had achieved great heights and laurels in the Indian pharmaceutical industry as a successful family-owned business. The feather in the cap for Ranbaxy is that it is one of the top ten global generic companies and is present in 23 of the top 25 pharmaceutical markets in the world. Having become a leader in the pharmaceutical industry with a spate of acquisitions in its fold, it came as a surprise that it is being acquired by Japanese company Daiichi Sankyo. This case study helps to analyse whether the divestments of Ranbaxy's family business to Daiichi Sankyo of Japan could promote growth and professionalism in Ranbaxy's family business. Will the deal offer a win-win situation for Daiichi and Ranbaxy and bring the expected synergies?

Pedagogical Objectives:

• To study the dynamics of the Indian family businesses.
• To understand the customer service functions of Ranbaxy.
• To analyse the impact of Ranbaxy's divestment.

Keywords : Divestiture; Ranbaxy; Daiichi Sankyo; Family business; Pharmaceutical industry; Acquisition deals by Ranbaxy; Generic business; Cholesterol-lowering lipitor; Volini; Proprietary drug development; R&D; Dr Reddy's Laboratories; Malvinder Singh; Ranbaxy's position in the Indian pharma industry